modified BFM-95 protocol

The **modified BFM-95 protocol** is a multi-agent chemotherapy regimen derived from the original Berlin–Frankfurt–Münster (BFM)-95 protocol, primarily used for the treatment of lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL), especially in children, adolescents, and young adults. The modification typically involves substituting pegaspargase for L-asparaginase to reduce immunogenicity and allergic reactions; replacing daunorubicin with pirarubicin to minimize cardiotoxicity; using citrovorum folinate rescue after high-dose methotrexate; and increasing intrathecal chemotherapy or high-dose methotrexate during maintenance instead of prophylactic cranial radiotherapy. The regimen consists of induction phases, consolidation/protocol M phase with high-dose methotrexate, reinduction phases, and a prolonged maintenance phase with oral mercaptopurine and methotrexate. It aims to improve tolerability while maintaining efficacy comparable to or better than standard protocols[1][3][5][6].

Other names

modified NHL-BFM-95 regimenmodified Berlin-Frankfurt-Münster 95 protocolmBFM-95mBFM95mBFM 95